Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience
出版年份 2023 全文链接
标题
Clinical significance of end of induction measurable residual disease monitoring in B‐cell acute lymphoblastic leukemia: A single center experience
作者
关键词
-
出版物
CYTOMETRY PART B-CLINICAL CYTOMETRY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-08-09
DOI
10.1002/cyto.b.22139
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Patrick A. Brown et al. Journal of the National Comprehensive Cancer Network
- Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
- (2020) Bachar Samra et al. Journal of Hematology & Oncology
- Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia
- (2020) Arun Kumar Arunachalam et al. LEUKEMIA & LYMPHOMA
- A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
- (2019) Renato Bassan et al. HAEMATOLOGICA
- A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10 6 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients
- (2019) Prashant R. Tembhare et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
- (2017) Giovanni Cazzaniga et al. HAEMATOLOGICA
- Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
- (2017) Giovanni Cazzaniga et al. HAEMATOLOGICA
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2016) D. Hoelzer et al. ANNALS OF ONCOLOGY
- Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
- (2016) Prisca Theunissen et al. BLOOD
- A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy
- (2016) Sindhu Cherian et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
- (2016) A. K. Arun et al. International Journal of Laboratory Hematology
- Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group
- (2016) Rob Pieters et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy
- (2016) Francesco Ceppi et al. PLoS One
- Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232
- (2015) M. J. Borowitz et al. BLOOD
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
- (2015) J. J. M. van Dongen et al. BLOOD
- Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
- (2015) N. Dhedin et al. BLOOD
- Personalized medicine in adult acute lymphoblastic leukemia
- (2015) D. Hoelzer HAEMATOLOGICA
- Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study
- (2015) Ching-Hon Pui et al. LANCET ONCOLOGY
- Personalized medicine in adult acute lymphoblastic leukemia
- (2015) D. Hoelzer HAEMATOLOGICA
- Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
- (2014) Ajay Vora et al. LANCET ONCOLOGY
- Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
- (2013) Ajay Vora et al. LANCET ONCOLOGY
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- (2012) N. Gokbuget et al. BLOOD
- Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country
- (2012) Nikhil Patkar et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Minimal Residual Disease–Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study
- (2012) Allen Eng Juh Yeoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2012) S Lee et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now